Supplementary Information

Metabolome-wide association of carotid intima media thickness in an Asian population cohort identifies FDX1 as a novel determinant of cholesterol metabolism and cardiovascular risk.

Nilanjana Sadhu^{1*}, Rinkoo Dalan^{1,2}, Pritesh R Jain¹, Chang Jie Mick Lee^{3,4}, Leroy Sivappiragasam Pakkiri⁵, Kai Yi Tay¹, Theresia H Mina¹, Dorrain Low¹, Yilin Min⁶, Matthew Ackers-Johnson^{3,4}, Thi Tun Thi⁶, Vishnu Goutham Kota⁷, Yu Shi⁶, Yan Liu⁶, Henry Yu⁷, Darwin Tay¹, Hong Kiat Ng¹, Xiaoyan Wang¹, Kari E Wong⁸, Max Lam^{1,9}, Xue Li Guan¹, Nicolas Bertin¹⁰, Eleanor Wong¹⁰, James Best¹, Rangaprasad Sarangarajan⁸, Paul Elliott^{1,11}, Elio Riboli^{1,11}, Jimmy Lee^{1,9}, Eng Sing Lee^{1,12}, Joanne Ngeow^{1,13}, Patrick Tan^{10,14}, Christine Cheung^{1,15}, Chester Lee Drum⁵, Roger SY Foo^{3,4,7}, Gregory A Michelotti⁸, Haojie Yu^{4,6}, Patricia A Sheridan⁸, Marie Loh^{1,11,16}, and John C Chambers^{1,11,14*}

¹Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore ²Department of Endocrinology, Tan Tock Seng Hospital, Singapore ³Cardiovascular Research Institute, National University Health System, Singapore ⁴Cardiovascular Metabolic Disease Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore ⁵Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore ⁶ Precision Medicine Translational Research Programme, and Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore ⁷Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore ⁸Metabolon, Inc., Durham, North Carolina, USA ⁹North Region, Institute of Mental Health, Singapore ¹⁰Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore ¹¹Department of Epidemiology and Biostatistics, Imperial College London, London, UK ¹²Clinical Research Unit, National Healthcare Group Polyclinic, Singapore ¹³Cancer Genetics Service, National Cancer Centre, Singapore

¹⁴Precision Health Research, Singapore, Singapore

¹⁵Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore

¹⁶National Skin Centre, Singapore

*Corresponding authors:

Nilanjana Sadhu (nilanjana.sadhu@ntu.edu.sg),

John C Chambers (john.chambers@ntu.edu.sg)

Description of tables in file "Supplementary Tables.xlsx"

Supplementary Table 1. Cohort Characteristics.

Supplementary Table 2. Quality control of metabolite and research phenotype data

Supplementary Table 3: Descriptive statistics for distribution of 883 metabolites in the overall dataset (N=8124) and stratified by ethnicity (Chinese N=5428, Indian N=1552, Malay N=1144).

Kruskal-Wallis (KW) and Anova tests were performed to test for differences in distribution of log-transformed metabolite abundances across the three ethnic groups.

Supplementary Table 4: Summary statistics for association analysis of 883 metabolites with mean cIMT in the overall dataset and stratified by ethnicity.

Overall analysis was adjusted for age, sex, ethnicity, and batch (Model 1). Ethnicity-specific analysis was adjusted for age, sex, and batch.

Supplementary Table 5: Summary statistics for 252 metabolites significantly associated with mean cIMT.

Model 1 was adjusted for age, sex, ethnicity, and batch (N=8124). Model 2 was adjusted for age, sex, ethnicity, batch, and traditional vascular risk factors: BMI, systolic BP, total cholesterol, T2D status, smoking status (N=8056). Model 3 was conducted in a subset of the cohort not on cholesterol-lowering drugs and adjusted for age, sex, ethnicity, batch, and traditional risk factors: BMI, systolic BP, total cholesterol, T2D status, smoking status (N=6689).

Supplementary Table 6: Summary statistics from GSMR of 126 metabolites (exposures, HELIOS study) against CAD (outcome; Koyama et al. 2020).

Supplementary Table 7: Summary statistics from GSMR of 126 metabolites (exposures, HELIOS study) against mean cIMT (outcome; Yeung et al. 2022).

Supplementary Table 8: Summary of results from TwoSampleMR.

Supplementary Table 9. Functional annotation of 1,259 candidate variants in the risk loci.

RegulomeDB score is a categorical score ranging from 1a to 7, indicating the following: 1a, eQTL + transcription factor (TF) binding + matched TF motif + matched DNase footprint + DNase peak; 1b, eQTL + TF binding + any motif + DNase footprint + DNase peak; 1c, eQTL + TF binding + matched TF motif + DNase peak; 1d, eQTL + TF binding + any motif + DNase peak; 1e, eQTL + TF binding + matched TF motif; 1f, eQTL + TF binding/DNase peak; 2a, TF binding + matched TF motif + matched DNase footprint + DNase peak; 2b, TF binding + any motif + DNase footprint + DNase peak; 2c, TF binding + matched TF motif + DNase peak; 3a, TF binding + any motif + DNase peak; 3b, TF binding + matched TF motif; 4, TF binding + DNase peak; 5, TF binding or DNase peak; 6, other; 7, not available.

Supplementary Table 10: Summary statistic of rs10488763 PheWAS against 168 NMR-based metabolites in Europeans and Asians.

Supplementary Table 11: Summary statistics from SMR analysis of metabolite 3BH5C GWAS in HELIOS and Whole Blood cis-eQTLs from GTEx V8 (results from chromosome 11)

Supplementary Table 12: Correlation of metabolite 3BH5C with other metabolites adjusted age, sex, ethnicity (results for correlations with Bonferroni-corrected P-value < 0.05 & absolute coefficient values greater than 0.2).

Supplementary Figures



Supplementary Figure 1. Distribution of mean cIMT in the study population (N=8,124).

Supplementary Figure 2. Distribution of quantified metabolites across different metabolite categories.



Supplementary Figure 3. MR estimates from inverse variance weighted leave-one-out sensitivity analysis of 3BH5C (exposure) on CAD (outcome).





Supplementary Figure 4. (a) Manhattan plot and (b) QQ plot of GWAS of 3BH5C in the HELIOS cohort (N=1,876; λ_{GC} =1.002).

In panel (a), Manhattan plot x-axis is displaying position of genetic variants on chromosome (hg38), and y-axis is displaying the strength of association of genetic variants with meancIMT. Horizontal red line indicates a GWAS threshold of $P=5x10^{-8}$. The top variant is rs2051466 (P = 7.9x10⁻⁴³). Figure 5. Bar plots showing correlation coefficient estimates of metabolite 3BH5C with (a) traditional vascular risk factors (Bonferroni-corrected P-value < 0.05). and (b) other metabolites (Bonferroni-corrected P-value < 0.05 and absolute correlation coefficients > 0.2), adjusted for age, sex, and ethnicity.

a.



b.



In panel (a), bars are coloured by risk factors that include(1) BMI: Body Mass Index [red], (2) DBP: Diastolic Blood Pressure [green], (3) SBP: Systolic Blood Pressure [green], (4) TC: Total Cholesterol [blue], (5) HDL-C: High Density Lipoprotein Cholesterol [blue], (6)LDL-C: Low Density Lipoprotein Cholesterol [blue], (7) TG: Triglyceride[blue], (8) HbA1C: Glycated hemoglobin [purple], (5) FGlucose: fasting plasma glucose [purple]. For all correlations, Bonferroni-corrected P-value < 0.05.

In panel (b), bars are coloured by the metabolite category indicated in the figure legend. This panel shows metabolites with Bonferroni-corrected P-value < 0.05 & absolute coefficient values greater than 0.2.





Volcano plot is displaying the association of rs10488763 effect allele T with 259 traits listed in the Biobank Japan PheWeb (https://pheweb.jp/). Vertical grey line indicates no effect. Associations highlighted in green are significant at a P-value threshold of $P=2x10^{-4}$ after correcting for 259 tests.





(a) Sequencing validation with two independent FDX1 knock-out (KO) human Embryonic Stem Cell (hESC) clones using two independent sgRNAs targeting Exon 1 splice junction, and a 16-bp deletion on Exon 1 respectively. (b) Schematic illustration of the human FDX1 transgene payload, over-expression (OE) and rescue by knocking into the safe-harbour Pansio-1 locus in H1-hESCs Pansio-1 Safe Harbour line.